Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial.

Lu W, Giobbie-Hurder A, Freedman RA, Shin IH, Lin NU, Partridge AH, Rosenthal DS, Ligibel JA.

Oncologist. 2019 Oct 14. pii: theoncologist.2019-0489. doi: 10.1634/theoncologist.2019-0489. [Epub ahead of print]

PMID:
31611333
2.

Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade.

Zhou J, Li J, Guleria I, Chen T, Giobbie-Hurder A, Stevens J, Gupta M, Wu X, Brennick RC, Manos MP, Hodi FS.

Cancer Immunol Immunother. 2019 Aug;68(8):1331-1340. doi: 10.1007/s00262-019-02370-4. Epub 2019 Jul 18.

PMID:
31317218
3.

Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.

Ippen FM, Grosch JK, Subramanian M, Kuter BM, Liederer BM, Plise EG, Mora JL, Nayyar N, Schmidt SP, Giobbie-Hurder A, Martinez-Lage M, Carter SL, Cahill DP, Wakimoto H, Brastianos PK.

Neuro Oncol. 2019 Nov 4;21(11):1401-1411. doi: 10.1093/neuonc/noz105.

PMID:
31173106
4.

The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders.

Ma C, Hodi FS, Giobbie-Hurder A, Wang X, Zhou J, Zhang A, Zhou Y, Mao F, Angell TE, Andrews CP, Hu J, Barroso-Sousa R, Kaiser UB, Tolaney SM, Min L.

Cancer Immunol Res. 2019 Jul;7(7):1214-1220. doi: 10.1158/2326-6066.CIR-18-0613. Epub 2019 May 14.

PMID:
31088848
5.

Impact of a Pre-Operative Exercise Intervention on Breast Cancer Proliferation and Gene Expression: Results from the Pre-Operative Health and Body (PreHAB) Study.

Ligibel JA, Dillon D, Giobbie-Hurder A, McTiernan A, Frank E, Cornwell M, Pun M, Campbell N, Dowling RJO, Chang MC, Tolaney S, Chagpar AB, Yung RL, Freedman RA, Dominici LS, Golshan M, Rhei E, Taneja K, Huang Y, Brown M, Winer EP, Jeselsohn R, Irwin ML.

Clin Cancer Res. 2019 Sep 1;25(17):5398-5406. doi: 10.1158/1078-0432.CCR-18-3143. Epub 2019 Apr 24.

PMID:
31018921
6.

Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control.

Alvarez-Breckenridge C, Giobbie-Hurder A, Gill CM, Bertalan M, Stocking J, Kaplan A, Nayyar N, Lawrence DP, Flaherty KT, Shih HA, Oh K, Batchelor TT, Cahill DP, Sullivan R, Brastianos PK.

Oncologist. 2019 May;24(5):671-679. doi: 10.1634/theoncologist.2018-0306. Epub 2019 Feb 22.

PMID:
30796152
7.

The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases.

Ippen FM, Alvarez-Breckenridge CA, Kuter BM, Fink AL, Bihun IV, Lastrapes M, Penson T, Schmidt SP, Wojtkiewicz GR, Ning J, Subramanian M, Giobbie-Hurder A, Martinez-Lage M, Carter SL, Cahill DP, Wakimoto H, Brastianos PK.

Clin Cancer Res. 2019 Jun 1;25(11):3374-3383. doi: 10.1158/1078-0432.CCR-18-3049. Epub 2019 Feb 22.

PMID:
30796030
8.

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F; International Breast Cancer Study Group and the Breast International Group.

Lancet Oncol. 2019 Mar;20(3):371-382. doi: 10.1016/S1470-2045(18)30812-X. Epub 2019 Feb 11.

PMID:
30765258
9.

MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas.

Nayyar N, White MD, Gill CM, Lastrapes M, Bertalan M, Kaplan A, D'Andrea MR, Bihun I, Kaneb A, Dietrich J, Ferry JA, Martinez-Lage M, Giobbie-Hurder A, Borger DR, Rodriguez FJ, Frosch MP, Batchelor E, Hoang K, Kuter B, Fortin S, Holdhoff M, Cahill DP, Carter S, Brastianos PK, Batchelor TT.

Blood Adv. 2019 Feb 12;3(3):375-383. doi: 10.1182/bloodadvances.2018027672.

10.

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.

Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, Shukla SA, Hu Z, Li L, Le PM, Allesøe RL, Richman AR, Kowalczyk MS, Abdelrahman S, Geduldig JE, Charbonneau S, Pelton K, Iorgulescu JB, Elagina L, Zhang W, Olive O, McCluskey C, Olsen LR, Stevens J, Lane WJ, Salazar AM, Daley H, Wen PY, Chiocca EA, Harden M, Lennon NJ, Gabriel S, Getz G, Lander ES, Regev A, Ritz J, Neuberg D, Rodig SJ, Ligon KL, Suvà ML, Wucherpfennig KW, Hacohen N, Fritsch EF, Livak KJ, Ott PA, Wu CJ, Reardon DA.

Nature. 2019 Jan;565(7738):234-239. doi: 10.1038/s41586-018-0792-9. Epub 2018 Dec 19.

11.

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.

Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber RD, Coates AS, Goldhirsch A, Thürlimann B, Regan MM; members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group.

J Clin Oncol. 2019 Jan 10;37(2):105-114. doi: 10.1200/JCO.18.00440. Epub 2018 Nov 26.

PMID:
30475668
12.

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.

Drago JZ, Lawrence D, Livingstone E, Zimmer L, Chen T, Giobbie-Hurder A, Amann VC, Mangana J, Siano M, Zippelius A, Dummer R, Goldinger SM, Sullivan RJ.

Melanoma Res. 2019 Feb;29(1):65-69. doi: 10.1097/CMR.0000000000000527.

PMID:
30376465
13.

BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation.

Li AG, Murphy EC, Culhane AC, Powell E, Wang H, Bronson RT, Von T, Giobbie-Hurder A, Gelman RS, Briggs KJ, Piwnica-Worms H, Zhao JJ, Kung AL, Kaelin WG Jr, Livingston DM.

Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):E9600-E9609. doi: 10.1073/pnas.1807112115. Epub 2018 Sep 25.

14.

Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.

Shah S, Luke JJ, Jacene HA, Chen T, Giobbie-Hurder A, Ibrahim N, Buchbinder EL, McDermott DF, Flaherty KT, Sullivan RJ, Lawrence DP, Ott PA, Hodi FS.

Melanoma Res. 2018 Dec;28(6):605-610. doi: 10.1097/CMR.0000000000000509.

PMID:
30211813
15.

Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.

Van Asten K, Slembrouck L, Olbrecht S, Jongen L, Brouckaert O, Wildiers H, Floris G, Van Limbergen E, Weltens C, Smeets A, Paridaens R, Giobbie-Hurder A, Regan MM, Viale G, Thürlimann B, Vergote I, Christodoulou E, Van Calster B, Neven P.

Oncologist. 2019 Feb;24(2):165-171. doi: 10.1634/theoncologist.2018-0176. Epub 2018 Aug 31.

PMID:
30171067
16.

A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer.

Kwan TT, Bardia A, Spring LM, Giobbie-Hurder A, Kalinich M, Dubash T, Sundaresan T, Hong X, LiCausi JA, Ho U, Silva EJ, Wittner BS, Sequist LV, Kapur R, Miyamoto DT, Toner M, Haber DA, Maheswaran S.

Cancer Discov. 2018 Oct;8(10):1286-1299. doi: 10.1158/2159-8290.CD-18-0432. Epub 2018 Aug 13.

17.

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.

Rodig SJ, Gusenleitner D, Jackson DG, Gjini E, Giobbie-Hurder A, Jin C, Chang H, Lovitch SB, Horak C, Weber JS, Weirather JL, Wolchok JD, Postow MA, Pavlick AC, Chesney J, Hodi FS.

Sci Transl Med. 2018 Jul 18;10(450). pii: eaar3342. doi: 10.1126/scitranslmed.aar3342.

PMID:
30021886
18.

Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma.

Wu X, Giobbie-Hurder A, Connolly EM, Li J, Liao X, Severgnini M, Zhou J, Rodig S, Hodi FS.

Oncoimmunology. 2018 Mar 13;7(7):e1440930. doi: 10.1080/2162402X.2018.1440930. eCollection 2018.

19.

ATP-binding cassette member B5 (ABCB5) promotes tumor cell invasiveness in human colorectal cancer.

Guo Q, Grimmig T, Gonzalez G, Giobbie-Hurder A, Berg G, Carr N, Wilson BJ, Banerjee P, Ma J, Gold JS, Nandi B, Huang Q, Waaga-Gasser AM, Lian CG, Murphy GF, Frank MH, Gasser M, Frank NY.

J Biol Chem. 2018 Jul 13;293(28):11166-11178. doi: 10.1074/jbc.RA118.003187. Epub 2018 May 22.

20.

Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis.

Elias R, Giobbie-Hurder A, McCleary NJ, Ott P, Hodi FS, Rahma O.

J Immunother Cancer. 2018 Apr 4;6(1):26. doi: 10.1186/s40425-018-0336-8.

21.

Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma.

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ.

Nature. 2018 Mar 14;555(7696):402. doi: 10.1038/nature25145.

22.

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients.

Subrahmanyam PB, Dong Z, Gusenleitner D, Giobbie-Hurder A, Severgnini M, Zhou J, Manos M, Eastman LM, Maecker HT, Hodi FS.

J Immunother Cancer. 2018 Mar 6;6(1):18. doi: 10.1186/s40425-018-0328-8.

23.

Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy.

Hong X, Sullivan RJ, Kalinich M, Kwan TT, Giobbie-Hurder A, Pan S, LiCausi JA, Milner JD, Nieman LT, Wittner BS, Ho U, Chen T, Kapur R, Lawrence DP, Flaherty KT, Sequist LV, Ramaswamy S, Miyamoto DT, Lawrence M, Toner M, Isselbacher KJ, Maheswaran S, Haber DA.

Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2467-2472. doi: 10.1073/pnas.1719264115. Epub 2018 Feb 16.

24.

An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer.

Miyamoto DT, Lee RJ, Kalinich M, LiCausi JA, Zheng Y, Chen T, Milner JD, Emmons E, Ho U, Broderick K, Silva E, Javaid S, Kwan TT, Hong X, Dahl DM, McGovern FJ, Efstathiou JA, Smith MR, Sequist LV, Kapur R, Wu CL, Stott SL, Ting DT, Giobbie-Hurder A, Toner M, Maheswaran S, Haber DA.

Cancer Discov. 2018 Mar;8(3):288-303. doi: 10.1158/2159-8290.CD-16-1406. Epub 2018 Jan 4.

25.

Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer.

Lykkesfeldt AE, Iversen BR, Jensen MB, Ejlertsen B, Giobbie-Hurder A, Reiter BE, Kirkegaard T, Rasmussen BB.

Acta Oncol. 2018 Jan;57(1):67-73. doi: 10.1080/0284186X.2017.1404126. Epub 2017 Dec 4.

PMID:
29202611
26.

Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy.

Lee H, Hodi FS, Giobbie-Hurder A, Ott PA, Buchbinder EI, Haq R, Tolaney S, Barroso-Sousa R, Zhang K, Donahue H, Davis M, Gargano ME, Kelley KM, Carroll RS, Kaiser UB, Min L.

Cancer Immunol Res. 2017 Dec;5(12):1133-1140. doi: 10.1158/2326-6066.CIR-17-0208. Epub 2017 Oct 27.

27.

An immunogenic personal neoantigen vaccine for patients with melanoma.

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ.

Nature. 2017 Jul 13;547(7662):217-221. doi: 10.1038/nature22991. Epub 2017 Jul 5. Erratum in: Nature. 2018 Mar 14;555(7696):402.

28.

Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.

Nishino M, Giobbie-Hurder A, Manos MP, Bailey N, Buchbinder EI, Ott PA, Ramaiya NH, Hodi FS.

Clin Cancer Res. 2017 Aug 15;23(16):4671-4679. doi: 10.1158/1078-0432.CCR-17-0114. Epub 2017 Jun 7.

29.

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.

Zhou J, Mahoney KM, Giobbie-Hurder A, Zhao F, Lee S, Liao X, Rodig S, Li J, Wu X, Butterfield LH, Piesche M, Manos MP, Eastman LM, Dranoff G, Freeman GJ, Hodi FS.

Cancer Immunol Res. 2017 Jun;5(6):480-492. doi: 10.1158/2326-6066.CIR-16-0329. Epub 2017 May 18.

30.

A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis.

L H Weischenfeldt K, Kirkegaard T, Rasmussen BB, Giobbie-Hurder A, Jensen MB, Ejlertsen B, Lykkesfeldt AE.

Acta Oncol. 2017 Sep;56(9):1161-1167. doi: 10.1080/0284186X.2017.1324211. Epub 2017 May 10.

PMID:
28488912
31.

Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.

Betof AS, Nipp RD, Giobbie-Hurder A, Johnpulle RAN, Rubin K, Rubinstein SM, Flaherty KT, Lawrence DP, Johnson DB, Sullivan RJ.

Oncologist. 2017 Aug;22(8):963-971. doi: 10.1634/theoncologist.2016-0450. Epub 2017 May 5.

32.

Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes.

Wu X, Li J, Connolly EM, Liao X, Ouyang J, Giobbie-Hurder A, Lawrence D, McDermott D, Murphy G, Zhou J, Piesche M, Dranoff G, Rodig S, Shipp M, Hodi FS.

Cancer Immunol Res. 2017 Jun;5(6):446-454. doi: 10.1158/2326-6066.CIR-16-0385. Epub 2017 May 4.

33.

Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.

Borgquist S, Giobbie-Hurder A, Ahern TP, Garber JE, Colleoni M, Láng I, Debled M, Ejlertsen B, von Moos R, Smith I, Coates AS, Goldhirsch A, Rabaglio M, Price KN, Gelber RD, Regan MM, Thürlimann B.

J Clin Oncol. 2017 Apr 10;35(11):1179-1188. doi: 10.1200/JCO.2016.70.3116. Epub 2017 Feb 13.

PMID:
28380313
34.

Risk of Bias and Heterogeneity-Reply.

Nishino M, Giobbie-Hurder A, Hodi FS.

JAMA Oncol. 2017 Jun 1;3(6):858-859. doi: 10.1001/jamaoncol.2017.0160. No abstract available.

PMID:
28334347
35.

A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis.

Dagogo-Jack I, Lanfranchi M, Gainor JF, Giobbie-Hurder A, Lawrence DP, Shaw AT, Sullivan RJ.

J Immunother. 2017 Apr;40(3):108-113. doi: 10.1097/CJI.0000000000000159.

PMID:
28221189
36.

Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.

Exley MA, Friedlander P, Alatrakchi N, Vriend L, Yue S, Sasada T, Zeng W, Mizukami Y, Clark J, Nemer D, LeClair K, Canning C, Daley H, Dranoff G, Giobbie-Hurder A, Hodi FS, Ritz J, Balk SP.

Clin Cancer Res. 2017 Jul 15;23(14):3510-3519. doi: 10.1158/1078-0432.CCR-16-0600. Epub 2017 Feb 13.

37.

Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.

Wu X, Giobbie-Hurder A, Liao X, Connelly C, Connolly EM, Li J, Manos MP, Lawrence D, McDermott D, Severgnini M, Zhou J, Gjini E, Lako A, Lipschitz M, Pak CJ, Abdelrahman S, Rodig S, Hodi FS.

Cancer Immunol Res. 2017 Jan;5(1):17-28. doi: 10.1158/2326-6066.CIR-16-0206. Epub 2016 Dec 21.

38.

A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.

Ibrahim N, Buchbinder EI, Granter SR, Rodig SJ, Giobbie-Hurder A, Becerra C, Tsiaras A, Gjini E, Fisher DE, Hodi FS.

Cancer Med. 2016 Nov;5(11):3041-3050. doi: 10.1002/cam4.862. Epub 2016 Oct 17.

39.

VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma.

Wu X, Giobbie-Hurder A, Liao X, Lawrence D, McDermott D, Zhou J, Rodig S, Hodi FS.

Cancer Immunol Res. 2016 Oct;4(10):858-868. Epub 2016 Aug 22.

40.

Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.

Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS.

JAMA Oncol. 2016 Dec 1;2(12):1607-1616. doi: 10.1001/jamaoncol.2016.2453. Review.

PMID:
27540850
41.

BRCA1/FANCD2/BRG1-Driven DNA Repair Stabilizes the Differentiation State of Human Mammary Epithelial Cells.

Wang H, Bierie B, Li AG, Pathania S, Toomire K, Dimitrov SD, Liu B, Gelman R, Giobbie-Hurder A, Feunteun J, Polyak K, Livingston DM.

Mol Cell. 2016 Jul 21;63(2):277-292. doi: 10.1016/j.molcel.2016.05.038. Epub 2016 Jun 30.

42.

Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.

Chirgwin JH, Giobbie-Hurder A, Coates AS, Price KN, Ejlertsen B, Debled M, Gelber RD, Goldhirsch A, Smith I, Rabaglio M, Forbes JF, Neven P, Láng I, Colleoni M, Thürlimann B.

J Clin Oncol. 2016 Jul 20;34(21):2452-9. doi: 10.1200/JCO.2015.63.8619. Epub 2016 May 23.

43.

Randomized trial of a physical activity intervention in women with metastatic breast cancer.

Ligibel JA, Giobbie-Hurder A, Shockro L, Campbell N, Partridge AH, Tolaney SM, Lin NU, Winer EP.

Cancer. 2016 Apr 15;122(8):1169-77. doi: 10.1002/cncr.29899. Epub 2016 Feb 12.

44.

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.

Ignatiadis M, Azim HA Jr, Desmedt C, Veys I, Larsimont D, Salgado R, Lyng MB, Viale G, Leyland-Jones B, Giobbie-Hurder A, Kammler R, Dell'Orto P, Rothé F, Laïos I, Ditzel HJ, Regan MM, Piccart M, Michiels S, Sotiriou C.

JAMA Oncol. 2016 Feb;2(2):217-24. doi: 10.1001/jamaoncol.2015.4377.

PMID:
26633571
45.

Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.

Munzone E, Giobbie-Hurder A, Gusterson BA, Mallon E, Viale G, Thürlimann B, Ejlertsen B, MacGrogan G, Bibeau F, Lelkaitis G, Price KN, Gelber RD, Coates AS, Goldhirsch A, Colleoni M; International Breast Cancer Study Group and the BIG 1-98 Collaborative Group.

Ann Oncol. 2015 Dec;26(12):2442-9. doi: 10.1093/annonc/mdv391. Epub 2015 Sep 19.

46.

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.

Buchbinder EI, Sosman JA, Lawrence DP, McDermott DF, Ramaiya NH, Van den Abbeele AD, Linette GP, Giobbie-Hurder A, Hodi FS.

Cancer. 2015 Nov 15;121(22):4007-15. doi: 10.1002/cncr.29622. Epub 2015 Aug 11.

47.

Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.

Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, Thürlimann B, Gelber RD, Colleoni M, Ejlertsen B, Debled M, Price KN, Regan MM, Coates AS, Goldhirsch A.

J Clin Oncol. 2015 Sep 1;33(25):2772-9. doi: 10.1200/JCO.2015.60.8133. Epub 2015 Jul 27.

48.

A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma.

Sullivan RJ, Ibrahim N, Lawrence DP, Aldridge J, Giobbie-Hurder A, Hodi FS, Flaherty KT, Conley C, Mier JW, Atkins MB, McDermott DF.

Oncologist. 2015 Jun;20(6):617-8. doi: 10.1634/theoncologist.2015-0105. Epub 2015 May 18.

49.

Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma.

Luke JJ, Donahue H, Nishino M, Giobbie-Hurder A, Davis M, Bailey N, Ott PA, Hodi FS.

Cancer Immunol Res. 2015 Sep;3(9):986-91. doi: 10.1158/2326-6066.CIR-15-0066. Epub 2015 May 5.

50.

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.

Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, O'Day SJ, Hamid O, Wolchok JD, Chapman PB, Sullivan RJ, Teitcher JB, Ramaiya N, Giobbie-Hurder A, Antonescu CR, Heinrich MC, Bastian BC, Corless CL, Fletcher JA, Hodi FS.

Clin Cancer Res. 2015 May 15;21(10):2289-96. doi: 10.1158/1078-0432.CCR-14-1630. Epub 2015 Feb 18.

Supplemental Content

Loading ...
Support Center